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Background: The knowledge of the pathophysiology of Lysosomal Storage Disorders has 
slowly increased, but information on their incidence is still scarce. The objective of this study 
was to evaluate the status and use of resources of these disorders in Spain from 1997 to 
2015. 
Methods: Records from 4,999 patients diagnosed with a Lysosomal Storage Disorder were 
extracted from a Spanish database containing data from public and private hospitals from 
1997 to 2015.  
Results: The database registered 2,441 patients with a LSD in Spain during the study period. 
Leukodystrophy, Krabbe disease, Pelizaeus-Merzbacher disease and sulfatide lipidosis 
represented, as a group, the most common disease cluster in Spain, affecting 26% of total 
patients. Average age of diagnosis of these disorders was 16.7 years. A sex bias was 
observed in most groups, with a proportion male/female of 60 to 40%. The direct medical 
cost of Lysosomal Storage Diseases was €5,686 per patient with an average cost per hospital 
admission of €4,923. Global costs displayed a growing tendency.  
Conclusions: Contrarily to worldwide disease incidence estimations, the group to include 
Krabbe disease registered the highest occurrence numbers in the study period, which 
makes evident the need for accurate regional disease incidence and patient demographic 
studies. Altogether, data suggests the need to improve LSDs diagnostic protocols, and 
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Lysosomal storage diseases (LSDs) are a group of metabolic disorders characterised by 
lysosomal dysfunction, which leads to the accumulation of macromolecules inside 
lysosomes. All LSDs are progressive, and in most cases there is a neurodegenerative course. 
Symptoms in other organ systems are frequent, including bones and joints, eyes, heart, 
kidneys, lungs, spleen, liver and skin [1]. The onset of most disorders is infantile or juvenile, 
although in a few cases an adult onset is possible. This description comprises over 70 
inherited diseases that altogether affect about one in 5,000 births, although individually the 
disorders are rare.  
LSDs are classified in several groups based on the type of disorder and age of onset of the 
first symptoms, key to diagnosis. A general disease classification includes glycogen storage 
diseases or glycogenosis, disorders of carbohydrate transport and metabolism, lipidoses, 
cerebral lipidoses, mucopolysaccharidoses, and leukodystrophy [2]. Two lipidoses were the 
first LSDs described, Gaucher disease was the first, in 1882, followed by Fabry disease in 
1898 [3-5]. Nonetheless, its recognition as LSDs took place after the 1960s, when the 
function and importance of lysosomes was characterised [6]. Since its description, the 
knowledge of LSDs pathophysiology has slowly increased, identifying multiple potential 
clinical targets. Enzyme replacement therapy (ERT) is the best-known therapeutic approach, 
widely investigated, and approved for the treatment of several LSDs, including Gaucher, 
Fabry, and three mucopolysaccharidoses [7].  
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Contrarily, epidemiological studies are not abundant, and in many countries, as in Spain, 
there is no information on the incidence of LSDs or individual disorders. Estimations of LSDs 
prevalence worldwide point at Fabry disease as the most common LSDs, with 1 in 40,000 to 
60,000 males, and no data on females. Pompe would affect about 1 in 40,000 people in the 
United States, and Gaucher disease would occur in 1 in 50,000 to 100,000 people [8]. 
Other world regions as North East Italy or Illinois have tried to establish the utility of new-
born screenings for certain LSDs (Pompe, Gaucher, Fabry, mucopolysaccharidosis type I and 
Niemann-Pick disease) with potential benefits derived from the screening [9, 10]; however, 
there is a lack of wider studies that determine disease incidence.  
In many occasions, significant disease occurrence differences have been reported among 
patients with diverse ethnicities and origins. For instance, Type 1 Gaucher disease can occur 
in 1 in 500 to 1,000 people in people of eastern and central European Jewish heritage [8]. 
Hence the importance of determining disease occurrence in a certain region in order to 
establish the utility of new-born standard screenings and optimal health care procedures. 
This study was designed to analyse LSDs occurrence in Spain, as well as to determine their 
economic impact from the National Health Service perspective. Thus, we reviewed patient 
characteristics, use of resources and hospitalisation costs of LSDs in Spain during 18 years 
using a national claims database. 
METHODS 
Records of patients diagnosed with LSD disorders were extracted from the Spanish claims 
database Minimum Basic Data Set (Conjunto Mínimo Básico de Datos (CMBD) [11], by 
means of the appropriate International statistical classification of diseases and related 
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health problems, 9th revision (ICD9) code. The CMBD database contains patient records 
from 192 private and 313 public hospitals from 1997 to 2015. Prior to extraction, 
parameters such as health centres and medical history identifiers were re-coded in order to 
maintain records anonymised, in accordance with the principles of Good Clinical Practice 
and the Declaration of Helsinki, and thus, ethics committee approval was not required (Law 
14/2007, July 3, on Biomedical Research, Spain). 
ICD9 codes utilised to select the data were: 271.0, 271.8, 272.7, 277.5, 330.0 and 330.1, 
corresponding to glycogenosis, other disorders of carbohydrate transport and metabolism 
(ODCTM), lipidoses, mucopolysaccharidosis, leukodystrophy and cerebral lipidoses 
respectively, all corresponding to LSDs disease clusters. 
Data analysis 
Data presentation and analysis are descriptive. Duplicate data was discarded to obtain 
information of individual patients, relying on the first record entry as the index event. Such 
records were employed to obtain single-patient information of disease occurrence (patient 
characteristics), direct medical cost per patient and financial scheme. Disease comorbidities 
have also been studied. The complete admission data was used to extract information on 
the nature of patient hospitalisations, diagnosis-related group (DRG) and cost per DRG. Via 
DRG, direct medical cost was calculated, which included treatment (examination, 




All available information has been included in the analyses, except for the extraction of 
direct medical costs, where 1997 and 1998 data was excluded to obtain a more consistent 
analysis. 
All statistical analyses were performed using Microsoft Excel© Professional Plus 2010 
(Microsoft Corporation, Redmond, WA, USA).   
RESULTS 
Characteristics of patients included in the database 
LSDs included in the study were determined by ICD9 codes, which claimed 47 disorders, 
listed in  
Table . 
Such codes identified 2,441 patients in the database with a LSD diagnosis. The most 
common disease group included Leukodystrophy, Krabbe disease, Pelizaeus-Merzbacher 
disease and sulfatide lipidosis with a total number of 624 patients diagnosed ( 
Table ). Lipidoses were in the second place, with 510 patients. This group includes diseases 
as Fabry and Gaucher. 
In terms of patients’ sex, certain differences were observed. Leukodystrophy, lipidoses, 
glycogenosis and mucopolysaccharidosis showed a proportion male/female of around 60 
to 40%. As for other specified disorders of carbohydrate transport and metabolism and 
cerebral lipidoses the proportion of male and female patients identified was of 53 to 47% 
and 54 to 46% respectively, presenting a smaller sex bias. Files with unknown sex and others 
represented less than 1% in all cases.  
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Patients’ age distribution varied among disease clusters. Patients diagnosed with 
glycogenosis had an average age of 15.75 years (SD ±19.91). For ODCTM it was of 13.23 
years (SD ±17.65). The average was of 26.22 years (SD ±23.58) for lipidoses, 9.31 years (SD 
±11.94) for mucopolysaccharidosis, 16.72 years (SD ±20.07) for leukodystrophy, and of 
11.94 years (SD ±17.02) for patients with cerebral lipidoses (Figure ). On the other hand, the 
number of diagnoses over time displayed a growing tendency for glycogenosis. These shifts 
are not likely to be representative of disease prevalence and further conclusions cannot be 
extracted due to a lack of information. Other clear tendencies were not observed (Figure ). 
LSDs regional distribution analysis showed that the Spanish Autonomous Community with 
the highest number of patients with glycogenosis, lipidoses, leukodystrophy and cerebral 
lipidoses was Madrid. Andalusia was the one with the most cases of mucopolysaccharidosis, 
and Catalonia of ODCTM (data not shown). 
Regarding disease comorbidities different symptoms are linked to the distinct disease 
clusters (Table 1). Mental disorder symptoms appear repeatedly among the 
mucopolysaccharidosis, leukodystrophy and cerebral lipidoses groups. Another repeated 
condition is hyperthension, which appears in patients with glycogenosis and lipidoses. In 
patients with ODCTM chronic renal disease is the most common comorbidity. 
Healthcare resources 
The analysis of the available admission data revealed information on the nature of patients’ 
hospitalisation. Programmed admissions were predominant for most patients, except in 
those with a diagnosis of leukodystrophy or cerebral lipidoses (Table ). Patients’ destination 
after discharge was predominantly to their residence; transfers to other hospitals or social 
9 
 
care centres, voluntary discharge, death and others represented less than 1% of the cases. 
Average hospitalisation time was 8 days, and readmission rates were around 6% in patients 
with lipidoses and mucopolysaccharidosis, and between 0.5 and 2% in patients included in 
other disease clusters. The service that attended the highest number of patients was 
paediatrics. 
The most common medical procedures registered in admission files were evaluated for each 
LSD cluster to obtain an approximation to disease management. In patients diagnosed with 
glycogenosis, lipidosis or a mucopolysaccharidosis the injection of a therapeutic substance, 
which includes enzyme replacement therapy (ERT), was the most repeated procedure, 
carried out in 31, 30 and 45% of patients’ admissions respectively. In patients with ODCTM, 
leukodystrophy and cerebral lipidoses the administration of therapeutic substances as ERT 
was performed only in 14, 4 and 7% of admissions respectively. In all cases, diagnostic 
techniques as abdomen echographies, radiographies and magnetic resonance of the brain 
and brain stem were significant. Enteral or parenteral infusion of concentrated nutritional 
substances took place in between 4 and 14% of admissions, with the highest percentages 
found in patients with cerebral lipidoses. Mechanical ventilation and oxygen enrichment 
were performed in around 8% of all admissions, with the higher percentage found too in 
patients with cerebral lipidoses (12%). Lastly, it is worth noting the relatively elevated 
presence of haemodialysis in patients with ODCTM (11%).  
Finally, the direct medical cost per patient was €5,686 with an average cost of €4,923 per 
hospital admission, being the costs of treating disorders of carbohydrate transport and 
metabolism the highest, and the costs associated to lipidoses the lowest (Table ). Global 
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medical costs increased slightly over time (Figure ), with an average annual direct medical 
cost of around €30,600 considering all LSDs. The Spanish social security system financed 
between 95 and 99% of the patients (Figure ). The remaining patients used private 
financing, mutual health care or other unspecified sources. 
DISCUSSION 
Information regarding LSDs epidemiology is still scarce in many countries, restricting the 
application of more specific health protocols, as new-born screening, that could allow a 
better handling of these diseases. LSDs are currently not included in new-born screening 
programs in Spain, although a previous study in the north of the country evaluated the 
viability of including Fabry disease in routine screenings [12]. Recommendations to include 
this disease in systematic screenings followed the study, but further assessment of the 
patient population was considered necessary in order to establish appropriate protocols for 
patients’ management. Herein, data provided by the CMBD database allowed a 
retrospective analysis of LSDs patients’ demographic information and disease occurrence in 
the country. Data revealed possible discrepancies with worldwide prevalence estimations. 
In Spain the most diagnosed diseases were, as a group, Leukodystrophy, Krabbe disease, 
Pelizaeus-Merzbacher disease and sulfatide lipidosis. Worldwide, Fabry disease is 
considered the most prevalent [8], whereas, in Europe, previous estimations situated 
Krabbe at 1 per 100,000 [13]. In terms of sex biases in the population, the fact that this 
disease cluster includes Pelizaeus-Merzbacher disease, linked to the X chromosome, could 
explain the sex ratio revealed for this disease group (60 to 40%). The same sex bias found 
in other groups is consistent with previous findings [1]; although not all existing reports 
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show such differences. This could be explained by a founder effect in some countries, which 
also justifies reported differences among distinct ethnic groups; for instance, glycogenosis 
(GSD II) mutations appear four times more than expected in the Netherlands [14]. This 
supports the importance of regional evaluations. Herein, as for patients’ regional 
distribution, Spanish Autonomous Communities with the highest number of patients 
corresponded to the most populated regions. 
Most LSDs are typically diagnosed during the first years of life given the severity of its 
symptoms. Spanish patients’ age distribution displayed in the present study suggests a late 
detection of these diseases, although a certain number of errors in patient records cannot 
be ruled out. Still, average age of diagnosis per group was between 9 and 26 years, which 
could be a result of small groups of patients showing the first symptoms during adolescence 
or early adulthood, together with a rate of misdiagnosis, which can worsen patients’ 
prognosis. Provided that the rate of misdiagnoses and delayed diagnoses caused the 
increase in this parameter, a major occurrence of preventable complications should be 
considered, together with the derived increased use of healthcare resources. For instance, 
listed complications derived from delayed Gaucher diagnosis include serious complications 
as progressive liver disease, chronic bone pain, growth failure and severe sepsis among 
others [15]. In parallel, the database allowed an analysis of patients’ disease comorbidities, 
which were repeatedly consistent with LSDs described symptoms. Mental disorders were 
found, typically present in patients with mucopolysaccharidosis, leukodystrophy and 
cerebral lipidoses [16-20], and hypertension can be common in patients with glycogenosis 
and lipidoses [21, 22]. As for patients with disorders of carbohydrate transport and 
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metabolism (ODCTM), kidney failure and an end-stage renal disease is frequent [23, 24]. 
Subsequently, an evaluation of current treatment protocols was considered of interest. 
Currently in Spain, there is a lack of specific clinical guidelines that describe protocols for 
suspected LSDs, only available for Fabry disease [25], and it is evident that the availability 
of effective and palliative treatment determines the efficiency of new-born screening 
programs and their viability. Medical procedures performed on admission were analysed as 
a rough approximation to disease management. The administration of therapeutic 
substances as ERT has been approved for the treatment of several LSDs [1] and prevails as 
the main therapy, especially significant in patients with glycogenosis, lipidosis or a 
mucopolysaccharidosis. Ventilation and oxygen enrichment were significant in all groups, 
although augmented in percentage when ERT was not applicable. This could be observed 
for Krabbe or Tay-Sachs disease, which have no specific treatments available and mostly 
receive symptomatic and supportive therapy [26]. It is noteworthy the percentage of 
patients with ODCTM receiving haemodialysis, a clear response to the symptoms of 
disorders as hyperoxaluria, in which renal damage is the principal outcome [27]. As a whole, 
disease management data did not reveal any significant discrepancies in Spanish clinical 
practices.  
An estimation of the burden that LSDs represent for the healthcare system is hardly 
obtainable given the wide number of disorders and their variety of clinical manifestations. 
Herein, we obtained LSDs direct medical cost via the analysis of the costs associated to each 
hospitalisation. The annual direct medical cost in Spain was €5,686 per patient between the 
years 1999 and 2015, with an average cost of €30,600 for all registered patients per year. 
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Similarly, in the UK it was estimated that the annual cost for LSDs patient care was €3,400-
13,700 per adult patient [28]. Moreover, studies that have measured the costs of enzyme 
replacement therapies have estimated annual costs of around €200,000 per patient [29]. 
The lack of accurate epidemiologic data however, hardens a realistic study of LSDs total 
burden, which would take into account indirect costs and their impact on society, although 
in this study they appear to have an increasing tendency. On the other hand, a previous 
analysis developed by a regional Spanish Health Department measured the costs that new-
born screening for Fabry, Gaucher, Pompe and Niemann-Pick would represent, a total sum 
of 0.53 million euros annually [30]. In Spain, disorders may be incorporated in standard 
new-born screenings given the following conditions: severe morbidity or mortality derive 
from delayed diagnosis, new-born detection is inefficient, effective or palliative treatment 
is available, incidence is over 1 in 10.000-15.000, procedure is cost-effective, there is a 
familiar and reproductive benefit derived, and clinical infrastructure is prepared [31]. 
Altogether, this study remarks the need to improve LSDs diagnosis, and supports their 
addition in screening programs. Patient descriptive parameters served as an approximation 
to the population characteristics, yet, in order to implement systematic screening, further 
research will be needed to determine recurrent genetic variants in the country.  
CONCLUSIONS 
Data obtained in this study remarks the need to improve LSDs diagnostic protocols, and 
supports the inclusion of these disorders in standard new-born screening programs. In 
addition, medical costs per patient, in an increasing tendency, considered together with the 
presumed indirect costs of the disease, suggest a cost-effective situation. Still, further 
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research will be required to determine the presence of specific genetic variants in the 
country that may lead to the selection of more precise screening tests.   
LIST OF ABBREVIATIONS 
CMBD: Conjunto mínimo básico de datos (Spanish claims database Minimum Basic Data 
Set). 
DRG: Diagnosis related group. 
ERT: Enzyme replacement therapy. 
ICD9: International statistical classification of diseases and related health problems, 9th 
revision code. 
LSD: Lysosomal storage disease. 
MPS: Mucopolysaccharidosis. 
ODCTM: Other specified disorders of carbohydrate transport and metabolism. 
Ethics Approval and Consent to Participate   
Data was anonymised prior to extraction, and thus, ethics committee approval was not 
required for this study (Law 14/2007, July 3, on Biomedical Research, Spain). 
Consent to Participate  
Not applicable. 
Consent for Publication 
Not applicable. 
Availability of Data and Materials  
The data that support the findings of this study is available from the Spanish Ministry of 
Health with restrictions applied.  
15 
 
 Conflict of interest 




JD contributes to the investigation by interpreting the economic current situation of LSDs 
in Spain, was a major contribution in the intellectual content revision and gave final 
approval of the version to be published. AM analysed the current occurrence rate of LSDs 
in Spain, analysed and interpreted the statistical data and was a major contributor in writing 
the manuscript. All authors read and approved the final manuscript. 
REFERENCES 
[1] Platt, F.M.; d'Azzo, A.; Davidson, B.L.; Neufeld, E.F.; Tifft, C.J. Lysosomal Storage 
Diseases. Nat. Rev. Dis. Primers, 2018, 4(1), 27. 
[2] Boustany, R.M. Lysosomal storage diseases – the horizon expands. Nat. Rev. 
Neurol. 2013, 9(10), 583-598. 
[3] Gaucher, P.C.E. De l’épithélioma primitive de la rate. Thése de Paris. 1882. 
[4] Anderson, W. A case of “angeiokeratoma”. Br. J. Dermatol. 1898, 10, 113-117. 
[5] Fabry, J. Ein Beitrag zurt Kenntnis der Purpura haemorrhagica nodularis (Purpura 
papulosa haemorrhagica Hebrae). Arch. Dermatol. Syph. 1898, 43, 187-200. 
[6] de Duve, D. Exploring cells with a centrifuge. Science. 1975, 189, 186-194.  
[7] Li, M. Enzyme replacement therapy: A review and its role in treating Lysosomal 
storage diseases. Pediatr. Ann. 2018, 47(5), e191-197. 
16 
 
[8] US National Library of Medicine, Genetics Home Reference. NIH. 2019; 
https://ghr.nlm.nih.gov/ (Accessed February 12, 2019).  
[9] Burlina, A.B.; Polo, G.; Duro, G.; Zizzo, C.; Dardis, A.; Bembi, B.; Cazzorla, C.; 
Rubert, L.; Zordan, R.; Desnick, R.J.; Burlina, A.P. Newborn screening for lysosomal 
storage disorders by tandem mass spectrometry in North East Italy. J. Inherit. 
Metab. Dis., 2017, 41(2), 209-219. 
[10] Burton, B.K.; Charrow, J.; Hoganson, G.E.; Waggoner, D.; Tinkle, B.; Braddock, 
S.R.; Schneider, M.; Grange, D.K.; Nash, C.; Shryock, H.; Barnett, R.; Shao, R.; 
Basheeruddin, K.; Dizikes, G. Newborn Screening for Lysosomal Storage Disorders 
in Illinois: The Initial 15-Month Experience. J. Pediatr. 2017, 190, 130-135. 
[11] Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. 
Conjunto Mínimo de Bases de Datos (CMBD). 
https://www.mscbs.gob.es/estadEstudios/estadisticas/cmbdAnteriores.htm 
(Accessed October 10, 2018). 
[12] Colon C, Ortolano S, Melcon-Crespo C, Alvarez JV, Lopez-Suarez OE, Couce ML, 
Fernández-Lorenzo JR. Newborn screening for Fabry disease in the north-west of 
Spain. Eur J Pediatr. 2017; 176(8):10756-1081 
[13] Orphanet, The portal for rare diseases and orphan drugs. Retrieved from: 
https://www.orpha.net/consor/cgi-bin/index.php?lng=EN (Accessed February, 
2019). 
[14] Ausems, M.G.; Verbiest, J.; Hermans, M.P.; Kroos. M.A.; Beemer, F.A.; Wokke, 
J.H.; Sandkuijl, L.A.; Reuser, A.J.; van der Ploeg, A.T. Frequency of glycogen 
17 
 
storage disease type II in The Netherlands: implications for diagnosis and genetic 
counselling. Eur. J. Hum. Genet. 1999, 7(6), 713-716. 
[15] Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in 
type 1 Gaucher disease: the need for greater awareness among hematologists-
oncologists and an opportunity for early diagnosis and intervention. Am J 
Hematol. 2007; 82(8):697-701. 
[16] Fernandes Filho, J.A.; Shapiro, B.E. Tay-Sachs disease. Arch. Neurol. 2004; 
61(9):1466-1468. 
[17] Muenzer, J. The mucopolysaccharidoses: a heterogeneous group of disorders 
with variable pediatric presentations. J. Pediatr. 2004, 144(5 Suppl), S27-34. 
[18] Brunetti-Pierri, N.; Scaglia, F. GM1 gangliosidosis: Review of clinical, molecular, 
and therapeutic aspects. Mol. Genet. Metab. 2008, 94(4), 391-396. 
[19] Graziano, A.C.; Cardile, V. History, genetic, and recent advances on Krabbe 
disease. Gene. 2015, 555(1), 2-13. 
[20] van Rappard, D.F.; Boelens, J.J.; Wolf, N.I. Metachromatic leukodystrophy: 
Disease spectrum and approaches for treatment. Best Pract. Res. Clin. Endocrinol. 
Metab. 2015, 29(2), 261-273. 
[21] Kleinert, J.; Dehout, F.; Schwarting, A.; de Lorenzo, A.G.; Ricci, R.; Kampmann, C.; 
Beck, M.; Ramaswami, U.; Linhart, A.; Gal, A.; Houge, G.; Widmer, U.; Mehta, A.; 
Sunder-Plassmann, G. Prevalence of uncontrolled hypertension in patients with 
Fabry disease. Am. J. Hypertens. 2006, 19(8), 782-787. 
18 
 
[22] Linhart, A.; Elliott, P.M. The heart in Anderson-Fabry disease and other Lysosomal 
Storage Disorders. Heart. 2007, 93(4), 528-535. 
[23] Harambat, J.; van Stralen, K.J.; Espinosa, L.; Groothoff, J.W.; Hulton, S.A.; 
Cerkauskiene, R.; Schaefer, F.; Verrina, E.; Jager, K.J.; Cochat, P.; European Society 
for Pediatric Nephrology/European Renal Association-European Dialysis and 
Transplant Association (ESPN/ERA-EDTA) Registry. Characteristics and outcomes 
of children with primary oxalosis requiring renal replacement therapy. Clin. J. Am. 
Soc. Nephrol. 2012, 7(3), 458-465. 
[24] van der Hoeven, S.M.; van Woerden, C.S.; Groothoff, J.W. Primary hyperoxaluria 
type 1, a too often missed diagnosis and potentially treatable cause of end-stage 
renal disease in adults: results of the Dutch cohort. Nephrol. Dial. Transplant. 
2012, 27(10), 3855-3862.  
[25] Calderón Sandubete E, Briones Pérez de la Blanca E, Alonso Ortiz del Río C, Marín 
León I, eds en nombre del Grupo de Trabajo para la Guía. Guía de práctica clínica 
multidisciplinar española sobre enfermedad de Anderson-Fabry. Ed. Enebro. 
Sevilla 2018. https://doi.org/10.1016/j.rce.2018.09.017. 
[26] Sun, A. Lysosomal storage disease overview. Ann .Transl. Med. 2018, 6(24), 476. 
[27] Lorenzo, V.; Torres, A.; Salido, E. Primary hyperoxaluria. Nefrologia. 2014, 34(3), 
273-424. 
[28] Wyatt, K.; Henley, W.; Anderson, L.; Anderson, R.; Nikolaou, V.; Stein, K.; Klinger, 
L.; Hughes, D.; Waldek, S.; Lachmann, R.; Mehta, A.; Vellodi, A.; Logan, S. The 
effectiveness and cost-effectiveness of enzyme and substrate replacement 
19 
 
therapies: a longitudinal cohort study of people with lysosomal storage disorders. 
Health Technol. Assess. 2012, 16(39), 1-543. 
[29] Beutler, E. Lysosomal storage diseases: Natural history and ethical and economic 
aspects. Mol. Genet. Metab. 2006, 88(3), 208-215. 
[30] Extended neonatal screening for Lysosomal diseases by mass spectrometry. 
Executive summary. Informes de evaluación de tecnologías sanitarias, AETSA 
2011/11. Consejería de Salud, Junta de Andalucía. 
[31] Marín Soria J L, Aldamiz-Echevarría L, Castiñeiras Ramos DE, Dalmau Serra J,  
Fernández Sánchez A, González Lamuño D, Juan Fita MªJ, Jiménez Jiménez LM, 
Pérez-Cerdá C. Programas de cribado neonatal en España: Actualización y 
propuestas de futuro. Documento de consenso. Ministerio de Sanidad, Gobierno 




Figure 1 Patients average age at diagnosis. 
Figure 2 Evolution of LSDs over time (1997 to 2015). 
Figure 3 Annual costs of LSDs per hospital admission (1999 to 2015). 






Table 1 LSDs clusters determined by ICD9. 
Table 2 Number and characteristics of patients diagnosed with a LSD.  
Table 3 Disease comorbidities in patients diagnosed with a LSD.  
Table 4 Admission origin and patients destination after discharge. 
Table 5 Costs associated with healthcare of patients with a LSD. Costs per hospital 




























































































































Table 1  
Glycogenosis 
Other specified disorders of carbohydrate 
transport and metabolism (ODCTM) 
Amylopectinosis Glycolic aciduria 
Glucose-6-phosphatase deficiency Fucosidosis 
Glycogen storage disease Primary hyperoxaluria  
McArdle's disease Mannosidosis 
Pompe disease Oxalosis 
von Gierke disease Essential benign pentosuria 
 Xylosuria 
 Xylulosuria 
Lipidoses Mucopolysaccharidosis (MPS) 
Chemically induced lipidosis MPS I  
Disease: MPS II  
     Anderson MPS III  
     Fabry MPS IV 
     Gaucher MPS VI  
     I cell [mucolipidosis I] MPS VII  
     lipoid storage NOS MPS IX 
     Niemann-Pick  
     pseudo-Hurler or mucolipidosis III  
     triglyceride storage, Type I or II  
     Wolman's or triglyceride storage, Type III  
Mucolipidosis II  
Primary familial xanthomatosis 
Leukodystrophy Cerebral lipidoses 
Krabbe disease Amaurotic (familial) idiocy 
Leukodystrophy: Disease: 
     NOS      Batten 
     globoid cell      Jansky-Bielschowsky 
     Metachromatic      Kufs' 
     Sudanophilic      Spielmeyer-Vogt 
Pelizaeus-Merzbacher disease      Tay-Sachs 


















Glycogenosis 487 19.95 62.22 37.78 15.75 
ODCTM 206 8.44 46.60 52.91 13.23 
Lipidoses 510 20.89 57.45 42.55 26.22 
Mucopolysaccharidosis 452 18.52 61.73 38.27 9.31 
Leukodystrophy 624 25.56 60.42 39.58 16.72 
Cerebral lipidoses 162 6.64 46.30 53.70 11.94 
 
 
Table 1  
Disease cluster Disease comorbidities % of patients 





ODCTM Chronic kidney disease 13.59 





 Splenomegaly 3.14 
Mucopolysaccharidosis Unspecified special symptoms a 5.09 
 Acute respiratory failure 3.98 
Leukodystrophy Unspecified special symptoms a 4.97 
 Corticoadrenal insufficiency 4.65 
Cerebral lipidoses Epilepsy  14.81 
 Unspecified special symptoms a 6.79 
a applies to communication disorders, hair plucking, lalling, lisping, masturbation, nail-





 Origin of admissions (%)  Destination after discharge (%) 






Glycogenosis 6.01 8.60  14.09 0.24 0.04 
ODCTM 1.70 2.10  3.59 0.06 0.00 
Lipidoses 5.62 8.81  13.69 0.21 0.09 
Mucopolysaccharidosis 7.14 8.71  15.29 0.18 0.05 
Leukodystrophy 6.73 4.18  9.88 0.31 0.04 








Glycogenosis 3,865 5,071 
ODCTM 8,362 9,685 
Lipidoses 3,066 3,898 
Mucopolysaccharidosis 4,301 5,508 
Leukodystrophy 4,985 5,071 
Cerebral lipidoses 4,959 4,886 
      Global costs 4,923 5,686 
 
 
